Company intelligence / Profile preview

DemeRx NB

Miami, Florida, United States

Ownership: Private
Development stage: Other

Overview

DemeRx NB is a clinical-stage biotechnology company focused on developing noribogaine for the treatment of opioid use disorder (OUD). A joint venture between DemeRx and ATAI Life Sciences, the company is advancing DMX-1002 (noribogaine), a non-hallucinogenic active metabolite of ibogaine, as a potential disease-modifying treatment for addiction. The program aims to reduce withdrawal symptoms and cravings, providing a bridge to long-term recovery for patients transitioning off opioids. By focusing on the pharmacology of noribogaine, DemeRx NB seeks to offer a safer and more regulated alternative to traditional ibogaine treatments.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

noribogaine

Partnerships

ATAI Life SciencesDemeRx

Beyond the preview

Go deeper on DemeRx NB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DemeRx NB.

Explore the full profile